← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Epigen Biosciences, Inc.
San Diego, CA
$21,182,379
Total funding
26
Grants
Funding over time
peak $3.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,182,379 · 26
By mechanism
R44$13,190,061 · 5
R43$4,567,214 · 13
R41$2,823,809 · 6
R21$408,388 · 1
U18$192,907 · 1
Investigators at Epigen Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease$1,322,759
R44 · FY2020 · AG
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease$1,169,102
R44 · FY2019 · AG
Novel therapy for Fragile X syndrome$1,157,216
R44 · FY2022 · MH
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH$1,041,548
R44 · FY2024 · DK
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$1,035,811
R44 · FY2021 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,838
R44 · FY2020 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,500
R44 · FY2018 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,274
R44 · FY2019 · DK
Novel therapy for Fragile X syndrome$998,958
R44 · FY2021 · MH
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$990,691
R44 · FY2022 · DK
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH$971,732
R44 · FY2023 · DK
Development of novel agents for the treatment of renal fibrosis$835,306
R44 · FY2015 · DK
Development of novel agents for the treatment of renal fibrosis$616,326
R44 · FY2014 · DK
Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery$550,864
R43 · FY2024 · NS
Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis$449,984
R43 · FY2021 · AG
New Therapy for the Treatment of Primary Biliary Cholangitis.$448,110
R43 · FY2023 · DK
Novel Treatment for Traumatic Brain Injury$417,267
R41 · FY2017 · NS
Novel therapy for Fragile X syndrome$399,938
R41 · FY2017 · MH
Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH$397,398
R43 · FY2021 · DK
Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes$390,335
R43 · FY2019 · DE